Title

Psychological Stress and skin aging: A review of possible mechanisms and potential therapies

Permalink

https://escholarship.org/uc/item/3j0766hs

Journal

Dermatology Online Journal, 19(6)

Authors

Dunn, Jeffrey H
Koo, John

Publication Date

2013

License

https://creativecommons.org/licenses/by-nc-nd/4.0/ 4.0

Peer reviewed

Psychological Stress and skin aging: A review of possible mechanisms and potential therapies

Jeffrey H. Dunn MD[1], John Koo MD[2]

Dermatology Online Journal 19 (6): 1

[1]University of Colorado, School of Medicine, [2]University of California, San Francisco, Department of Dermatology

Correspondence:
Jeffrey H. Dunn, MD: jeffhdunn@gmail.com

Abstract

The link between psychological stress and aging is intuitive although the underlying mechanisms are not well defined. Evidence suggests that chronic psychological stress stimulates the autonomic nervous system, renin-angiotensin system, and the hypothalamic-pituitary-adrenal axis when the body attempts to resolve perceived threats to homeostasis. Prolonged activation of these pathways can result in chronic immune dysfunction, increased production of reactive oxygen species, and DNA damage, which are known to contribute to the again of skin and other tissues.

Despite the lack of conclusive evidence directly linking psychological stress to skin aging, mechanisms by which stress leads to immune dysfunction, oxidative radicals, and ultimately DNA damage via neuronal, endocrine, and immune modulation may present a possible intervention for skin aging. In addition to the wide array of anti-oxidant therapies being developed to combat aging, the topical use of beta-blockers such as timolol, angiotensin receptor blockers such as valsartan, glucocorticoid blockers such as mifepristone, and cholinergic modulators including botulinum toxin, might be potential therapeutic strategies to prevent skin aging. Given the current understanding of these pathways, it would be premature to utilize such modalities for prevention of skin aging at this time, but future research into this type of topical pharmacologic anti-aging intervention may be promising.

Key Words: Psychological stress, anti-aging

Introduction

This review will cover a diverse array of systems that are likely to connect the phenomenon of psychological stress to aging of the skin and based on these possible connections will speculate on potential novel skin anti-aging interventions. Although direct evidence linking psychological stress to aging is still emerging, the effect of psychological stress on the autonomic nervous system, renin-angiotensin system (RAS), and hypothalamus-pituitary-adrenal (HPA) system is well established. These systems are known to contribute to inflammation, oxidative stress and DNA damage, which are known aging mechanisms in all tissues including the skin.

Methods

Studies were identified by searching Pubmed MEDLINE. The search strategy was based on the concepts of "stress", "skin", and "aging" with multiple subject headings and text words to describe each concept. They include terms such as psychological, emotional, ethnicity, senescence, infection, cancer, and disease. No year limits were applied to the searches and therefore included the full year range of the database up to September 2011, when the search was conducted. No language limits were applied although only English-language studies were reviewed.

Results

*The connection between stress and aging*

Biological aging is a process of progressive decline in organismal fitness and cellular function, which contribute to the development of age-related diseases and eventual death [1]. Theories of aging center around models relating free-radical formation, immune dysfunction, and cumulative DNA damage [2]. Several diseases commonly considered as models for aging [diabetes, atherosclerosis, rheumatoid arthritis, osteoporosis, and the progeroid syndromes] are also characterized by pathophysiology involving imbalances of reactive oxidation species formation, innate and adaptive immunity, and DNA damage/repair processes [2-17]. Furthermore, chronic immune dysfunction and reactive oxidation species (ROS) inhibit genetic and cellular repair, contributing to a synergistic and cumulative decline in cellular and physiological function [18].

Stress is the phenomenon in which a potentially harmful stimulus results in a physiological or psychological disturbance to homeostasis [19-21]. Psychological stress can modulate the body's defenses, depending on such factors as the duration of the stressful condition, as well as the individual's reaction to or perception of the situation [22]. In attempting to preserve homeostasis, the body activates several well-known mechanisms in response to psychological stress including the "fight-or-flight" sympathetic adrenal medullary (SAM) pathway, the renin-angiotensin system (RAS) pathway, the hypothalamic-pituitary-adrenal (HPA) pathway, and the parasympathetic (cholinergic) pathway [20, 23, 24].

The body initially responds to stress by activating the autonomic nervous system to release catecholamines (e.g. epinephrine and norepinephrine) from the adrenal medulla and by triggering the pituitary gland to release a surge of adrenocorticotrophic hormone (ACTH), which causes the adrenal cortex to release glucocorticoids (cortisol). This has been studied and quantitatively measured in a number of studies dating back to the 1970s. For example, human studies have shown that stressful situations including puzzle solving, mental arithmetic, novel environments, or threatening presences result in rising levels of catecholamines, angiotensin, cortisol, and acetylcholine [25, 30-36]. Studies in animals similarly demonstrate that exposure to temperature extremes, predators, sleep deprivation, or immobilization increase catecholamine, angiotensin, cortisol, and acetylcholine release [20, 32-34, 36-38].

Skin aging

Skin aging is a function of both chronological aging and photoaging [29]. Both chronological and photoaging are cumulative processes. However, photoaging is primarily a function of sun exposure and pigmentation, whereas chronological aging is primarily a function of time [29]. Although psychological stress is presumably a component of chronological skin aging, evidence directly connecting psychological stress to skin aging is limited. What can be demonstrated, however, are proven mechanisms by which psychological stress can lead to neurological, endocrine, and immune changes and how these changes cumulatively contribute to the common mechanisms by which aging is known to occur (See Figure 1).

Figure showing the pathway from Chronic stress through Sympathetic Activation, Renin–Angiotensin System (RAS), Hypothalamus Pituitary Adrenal (HPA) Axis, and Parasympathetic activation, leading to Skin Aging (Atrophy, Cancer, Atherosclerosis).

The skin and nervous system are both derived from the same primary germ layer during embryonic development and skin cells express proteins that are also common to neuronal signaling pathways [23, 25]. For example, acetylcholine (Ach) is a ubiquitous neurotransmitter in the central and autonomic nervous system that is also involved in immunomodulation of the skin. Proteins responsible for Ach signaling, synthesis, and degradation are also found in keratinocytes and mast cells [23, 25]. Moreover, melanin is a downstream product of phenylalanine, the essential amino acid fundamental to dopamine, epinephrine, and norepinephrine synthesis; proteins responsible for catecholamine and melanin metabolism are found in melanocytes [26]. Melanin production is furthermore stimulated by melanocortin as well as ACTH, a hormone that is produced in the pituitary [27, 28]. So it is perhaps not surprising that central nervous system activities can also modulate cellular function in the skin [20, 23, 25].

From this basic overview of the link between psychological stress and modulation of catecholamines, angiotensin, glucocorticoids, and acetylcholine this review will now shift focus to the mechanisms by which these molecules can lead to skin aging and potential skin anti-aging interventions that modify these pathways.

Psychological Stress, the Sympathetic Adrenal Medulla pathway, and DNA damage--Psychological stress activates the autonomic nervous system to trigger release of catecholamines [e.g. epinephrine and norepinephrine] from the adrenal glands [19, 20, 39]. In the short term, epinephrine and norepinephrine increase pulse, respiratory rate, and blood pressure. But over the long term, these catecholamines can have many negative effects on the body [24]. Among other problems, long-term increases in catecholamines can cause DNA damage, immunosuppression, tumor growth, dementia, and cardiovascular disorders [18, 19, 40-45].

The mechanisms by which stress-induced catecholamine release causes DNA damage and immunosuppression are perhaps the most well defined molecular pathways linking stress and aging [19, 45]. A recent report demonstrated that catecholamines, working through β2-receptors, result in DNA damage [19]. It is important to note that in this model for chronic psychological stress, mice were continuously infused for four weeks with the β2-receptor-agonist isoproterenol, a synthetic analogue of epinephrine. The group found that prolonged isoproterenol infusion damages histones, which are the primary protein component housing DNA in the nucleus. Furthermore, it was shown that isoproterenol infusion leads to DNA damage specifically in the thymus, an immune organ, which reacts prominently to acute and chronic psychological stress. Moreover, this study demonstrated isoproterenol infusion leads to decreased levels of p53 in the cells of the thymus. This is significant because p53 is a protein that is well established to be involved in genome protection and maintenance by preventing proliferative gene expression, DNA mutations, and cell division and is implicated in etiology of various types of cancer, including skin cancer [19,

46-49]. The study authors further suggest that this mechanism may just be one of several by which chronic stress in the form of persistent catecholamine excess may contribute to DNA damage. From a medical standpoint, this study is interesting because a wide-variety of beta-2 [β2] blockers are currently utilized for treatment of cardiovascular disease and have been suggested as a potential therapeutic option to promote wound healing in the skin [50, 51].

Acute vs. Chronic Stress: The catecholamine system--There is an important distinction between acute and chronic stress in terms of how the body maintains homeostasis. Acute stressors are thought to be beneficial whereas chronic stress is thought to be detrimental to the body's ability to fight disease, maintain homeostasis, and prevent aging. Acute stress is thought to mobilize immune cells, promote their migration to damaged tissues, and increase both cellular and humoral adaptive immunity [21, 22, 24, 52-59].

Although acute stress is beneficial in such situations as recovery from wounds or infection, it is generally accepted that protracted stressful conditions [chronic stress or repeated episodes of acute stress] have the opposite effect, namely immunosuppression, leading to increased infections and diseases [1, 20, 22, 24, 45, 60-70]. In a healthy person, for example, epinephrine released in response to acute stress has a stimulatory effect on chemotaxis, which may prepare the immune system to respond to pathogens [22, 71, 72]. In chronically stressed individuals, however, persistent adrenergic stimulation continuously mobilizes immune cells without rest. When an acute stress arises in this abnormal setting, catecholamine stimulation is unable to provide a boost to chemotaxis when it is most needed [20, 22, 24, 73-75].

Acute vs. Chronic Stress: The renin-angiotensin system--The renin-angiotensin system [RAS] is activated primarily in response to decreased renal blood flow, but is also activated by signals generated from the sympathetic and HPA systems in response to physical or psychosocial stressors [20, 34, 35, 76]. The physiology of the RAS begins with juxtaglomerular cells of the kidney that release renin, which in turn activates angiotensin II to cause vasoconstriction, release of aldosterone and antidiuretic hormone, and other downstream effects. Prolonged or repetitive stress-induced activation of RAS may lead to vascular inflammation and atherosclerosis [20]. Inflammatory cells commonly express the angiotensin II type 1 receptor [AGTR1] and it has been shown that angiotensin II modulates the behavior and distribution of inflammatory cells [20, 77]. Inflammation is a component of the initiation and progression of atherosclerosis and prolonged activation of RAS may contribute to immune-mediated vascular damage [20, 78, 79].

Angiotensin II exerts its effects through a variety of intracellular mechanisms. Working through AGTR1, protein kinase C [PKC] and Janus kinase [JaK] pathways, angiotensin II stimulates monocytes and macrophages to increase the production of various cytokines and inflammatory mediators [20, 80-89]. Prolonged activation of the RAS may also lead to cancer tumorogenesis; angiotensin II has been shown to promote angiogenesis and invasion in melanoma and breast cancer cell lines [90-92].

The renin-angiotensin system and oxidative stress--Angiotensin II can stimulate NADPH-oxidase-dependent ROS production in neutrophils through several molecular pathways including MAP kinase, ERK, and phospholipase A2 [20, 93-95]. Angiotensis II also inhibits the synthesis of the antioxidant heme oxygenase-1 in human neutrophils [20, 96]. Oxidative stress also plays an important role in chronological and photoaging in the skin [97-102]. In normal unstressed cells, there is a balance of reactive oxygen species (ROS) production from the mitochondria and expression of antioxidant enzymes, including catalase, superoxide dismutase (SOD), and glutathione peroxidase [103, 104]. When a cell comes under stress, however, this balance is disrupted and the unchecked free radicals can alter cellular behavior [103, 105, 106]. Diminished antioxidant capacity in the face of increased ROS also activates the transcription of NF-κβ, which promotes transcription of a variety of inflammatory and proliferative genes [17, 79, 107]. Angiotensin II itself can also directly increase NF-κβ activity [20, 89].

The end result of these pathways is an imbalance of oxidative free radicals with resultant DNA damage and increased expression of proliferation genes and inflammatory cytokines, which can lead to aging and age related diseases such as cancer and atherosclerosis [2-17]. Inhibiting angiotensin II or the AGTR1 receptor has been demonstrated to block these ROS generating pathways. Valsartan blockade of the AGTR1 receptor significantly decreases ROS generation in neutrophils isolated from human subjects [20, 108]. Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers also decrease NF-κB DNA binding activity in monocytes, neutrophils, and endothelial cells [20, 83, 108] (See Figure 1). These findings are interesting given the variety of angiotensin receptor blockers (e.g. Valsartan) that are currently utilized for treatment of cardiovascular disease. Moreover, in vitro and observational studies show that ACE-inhibitors and angiotensin receptor blockers can inhibit several types of cancer, including skin cancer [109-111]. A large 2008 cohort study of patients at high risk for basal cell and squamous cell carcinoma found that patients using a systemic ACE-inhibitor or angiotensin receptor blocker developed these cancers at a significantly lower rate than non-users. Although this study did not demonstrate causality, the authors speculate that

the association results from blocking angiotensin pathways because other anti-hypertensive medications did not have the same effect [109].

Stress and the HPA axis--The hypothalamic-pituitary-adrenal (HPA) axis responds to psychological or physiological stress by secreting corticotrophin releasing hormone [CRH] and ACTH, mediating a release of glucocorticoids from the adrenal cortex [22]. Under conditions of chronic stress, persistently high levels of glucocorticoids have many negative effects including immunosuppression, tissue atrophy and acceleration of the aging process in nearly all tissues including skin [24, 112-114]. Glucocorticoid excess, either from exogenous medication or endogenous disease [e.g. Cushing's syndrome] has several deleterious effects on the skin [115]. Glucocorticoids can cause atrophy and impaired wound healing by interfering with keratinocyte and fibroblast function [115-118]. This results from suppression of hyaluronan synthase and depletion of glycosaminoglycans, as well as reduced collagen and lipid production. These structural transformations clinically manifest as atrophy and thinning of the skin, increased transepidermal water loss related to disruption to the skin permeability barrier, and easy bruising with impaired wound healing [115-122]. Of note, these effects are similar to aging of the skin in the geriatric population [123, 124].

At the molecular level it is thought that glucocorticoids mediate these effects through a variety of mechanisms mediated by the intracellular glucocorticoid receptor [GCR][118]. Glucocorticoid binding to the GCR results in its translocation to the nucleus, where it modulates transcription either by directly binding to DNA or through protein-protein interactions with transcription factors themselves [118, 125, 126]. Among the transcription factors affected are activator protein-1, Smad3, and NF-κβ [127-129]. Genes affected by these interactions include those needed for lipid synthesis as well as production of extracellular matrix proteins [collagens, proteoglycans and elastins] [118, 130, 131].

Perhaps not surprisingly, glucocorticoid blockers have also been shown to prevent psychological stress-induced changes in skin structure and function. A 2006 study exposed hairless mice to psychological stress in the form of continuous visible light and radio noise for 48 hours. The authors reported that GCR blockade with mifepristone [Mifeprex®] as well as CRH receptor inhibition with antalarmin prevented or reversed several psychological stress-induced skin abnormalities including keratinocyte proliferation, permeability barrier homeostasis, and stratum corneum integrity [132].

Stress and the Cholinergic Pathway--Less is known about the relationship between stress, cholinergic signaling, and aging. The parasympathetic nervous system activation mediates a variety of functions, including muscle contraction and glandular secretion, as well as changes in cell proliferation and migration [23, 133, 134]. Activation of the parasympathetic nervous system releases acetylcholine (Ach) from nerve fibers, which activates nicotinic ACh receptors and/or muscarinic ACh receptors in target organs [23, 25]. Immune cells, including dendritic cells, mast cells, neutrophils, and macrophages, possess the components of cholinergic signaling pathways [23, 135]. Localized cholinergic signaling can also suppress of skin immunity, resulting in infections and delayed wound healing [23, 26, 136]. Dysregulated keratinocyte production of antimicrobial peptides such as cathelicidin and defensin resulting from persistent Ach activity can contribute to a variety of diseases including bacterial infection as well as atopic dermatitis, psoriasis, and pemphigus [23, 121, 137, 138]. Although studies of anticholinergic medications for prevention of skin aging are lacking, a wide variety of anticholinergic drugs are currently utilized in dermatology, including topical antihistamines such as diphenhydramine, oxybutynin (hyperhidrosis), and botulinum toxin.

Discussion

The data reviewed here illustrate that psychological stress activates the SAM, RAS, HPA and cholinergic systems, which contribute to immune dysfunction, ROS, and DNA damage [19, 20, 25, 132]. Moreover, the known mechanisms by which immune dysfunction, ROS, and DNA damage contribute to senescence are intriguing from the viewpoint of aging intervention [2-17]. Cumulative damage to cellular and DNA repair mechanisms play a role in the declining ability of the body to repair itself. Substantial evidence demonstrates that synergistic and cumulative DNA damage caused by inflammation and oxidative free radicals results in part from a progressive age-related failure of cellular maintenance and repair systems to respond appropriately to cell stress [1, 139-145]. Furthermore, oxidative stress specifically damages promoters for the genes responsible for cellular maintenance, including antioxidant and DNA repair enzymes [18]. In the skin, unchecked free radicals can destroy cells and cellular components including collagen and elastin fibers resulting in formation of furrows and wrinkles and skin disorders including cancer [97-102].

Although acute mild stress-induced stimulation (hormesis) of these repair mechanisms, including exercise, caloric restriction, and brief UV irradiation, is recognized as having anti-aging effects [1, 139, 146-148], chronic or repetitive stress exacerbates aging through cumulative processes of inflammation, oxidative stress and DNA damage [3, 149-153]. Prolonged activation of the

sympathetic, RAS, HPA, and parasympathetic systems owing to chronic stress may result in suppression of the immune system's ability to appropriately respond to acute psychological stressors [20, 23].

Crosstalk between neuronal, endocrine, and immunologic systems is also postulated to regulate how the skin responds to acute versus chronic stress, which can modulate its response to injury and disease [20]. Repetitive cycles of chronic stress, inflammation, and disease in concert with persistent stress-induced catecholamine and glucocorticoid excess may result in diminished keratinocyte and fibroblast function that underlies the aging process of the skin [60, 112, 152-162]. See Figure 1.

As mentioned above, the somewhat paradoxical phenomenon in which chronic stress causes immunosuppression in the setting of a low-grade inflammatory state might be explained by interaction between the HPA and renin-angiotensin system [RAS]. Whereas glucocorticoids are known to be broadly immunosuppressive, renin and angiotensin released in response to chronic stress may allow for a pro-inflammatory state to exist in the setting of immunosuppression [20, 21, 163]. In other words, persistent glucocorticoid elevation broadly suppresses the immune system. But simultaneous chronic activation of the RAS may allow for a low-level inflammatory state to exist even while the adaptive immune response remains suppressed by persistent glucocorticoid release [20, 21, 127-129, 164]. The net result may be a situation in which persistent release of pro-inflammatory cytokines cause indiscriminate skin damage that is compounded by the failure of the adaptive immune system to specifically respond to infection or disease. In the context of chronic stress, cholinergic suppression of antimicrobial activity in the setting of catecholamine and glucocorticoid-induced immunosuppression as well as angiotensin-induced inflammation may further contribute to the phenomenon of a persistently active but ineffective and deleterious immune response [21, 25, 165].

There is currently an abundance of research focused on skin anti-aging therapy including vitamins, resveratrol, retinoids, estrogen agonists, anti-glycation compounds, and polyphenols [166-177]. Could beta-blockers, angiotensin receptor blockers, glucocorticoid antagonists, or cholinergic modulators be added to the current list of candidates with potential for fighting skin aging? From a dermatology point of view, it is a provocative idea. Because stress can lead to prolonged catecholamine, angiotensin, glucocorticoid, and cholinergic activity and because prolonged activity of these hormones is associated with aging and age-associated disease, we might prevent or delay skin aging by topical application of one or more of these FDA-approved drugs. The potentially beneficial medications would include beta-blockers, angiotensin receptor blockers, glucocorticoid receptor antagonists, or anticholinergics. The idea that systemic drugs developed for non-dermatologic indications may have a dermatologic application is not new. The beta-blocker propranolol is systemically used for treatment of vascular tumors in the skin [178-180]. The systemic anticholinergic oxybutynin [Ditropan®] blocks muscarinic Ach receptors and was developed for urge incontinence, but is now prescribed for hyperhidrosis [181, 182]. Finasteride [Propecia®], an anti-androgenic hormone initially developed for prostate hypertrophy, is also used for pattern alopecia [183].

Moreover, topical formulations of medications are known to have benefits that were initially noted as side effects. The antihypertensive minoxidil [Rogaine®] is now used topically for treatment of alopecia [184]. The beta-blocker timolol [Timoptic®] is commonly used for topical treatment of glaucoma [185]. The prostaglandin analog bimatoprost [Latisse®] was, in turn, developed for treatment of glaucoma, but is now used to darken and lengthen eyelashes [186]. Additionally, the use of topical precursors to aspirin, a non-steroidal anti-inflammatory drug [NSAID] for prevention of skin aging have been studied with promising results [187].

Conclusion

As the fundamental molecular pathophysiology underlying various disease processes including aging becomes better understood, it seems more plausible that currently available modifiers of these stress-related hormonal pathways may be useful for prevention of skin aging. For example the molecular pathophysiology underlying psoriasis and atherosclerosis, two diseases, which are known to be exacerbated by stress, have been shown to have many similarities [188, 189]. Furthermore, ACE inhibition, mineralocorticoid blockade, and beta-blockade can slow and potentially reverse age and congestive heart failure-associated cardiavascular remodeling, a process characterized by collagen degradation, apoptosis, and fibrosis [190, 191]. Skin manifestations of various stress-related gastrointestinal, renal, and neurological diseases are also well known. Thus it seems at least conceivable that drawing a parallel between age-related disease pathways may potentially yield new avenues for therapeutic intervention with both cosmetic and clinical medical applications.

Figure 1. Hypothetical pathways linking chronic psychological stress with skin aging [19-21, 23, 25].

References

1.   Lima CF, Pereira-Wilson C, Rattan SI. Curcumin induces heme oxygenase-1 in normal human skin fibroblasts through redox signaling: relevance for anti-aging intervention. Mol Nutr Food Res. 2011;55[3]:430-42. doi: 10.1002/mnfr.201000221. PubMed PMID: 20938987.
2.   Goto M. Inflammaging [inflammation + aging]: A driving force for human aging based on an evolutionarily antagonistic pleiotropy theory? Biosci Trends. 2008;2[6]:218-30. PubMed PMID: 20103932.

3.   Akase T, Nagase T, Huang L, Ibuki A, Minematsu T, Nakagami G, et al. Aging-Like Skin Changes Induced by Ultraviolet Irradiation in an Animal Model of Metabolic Syndrome. Biol Res Nurs. 2011. doi: 1099800411401013 [pii] 10.1177/1099800411401013. PubMed PMID: 21444332.

4.   Weindruch R, Sohal RS. Seminars in medicine of the Beth Israel Deaconess Medical Center. Caloric intake and aging. N Engl J Med. 1997;337[14]:986-94. doi: 10.1056/NEJM199710023371407. PubMed PMID: 9309105; PubMed Central PMCID: PMCPMC2851235.

5.   Masoro EJ. Overview of caloric restriction and ageing. Mech Ageing Dev. 2005;126[9]:913-22. doi: S0047-6374[05]00078-3 [pii]
10.1016/j.mad.2005.03.012. PubMed PMID: 15885745.

6.   Dinarello CA. Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. Am J Clin Nutr. 2006;83[2]:447S-55S. doi: 83/2/447S [pii]. PubMed PMID: 16470011.

7.   Licastro F, Candore G, Lio D, Porcellini E, Colonna-Romano G, Franceschi C, et al. Innate immunity and inflammation in ageing: a key for understanding age-related diseases. Immun Ageing. 2005;2:8. doi: 1742-4933-2-8 [pii]
10.1186/1742-4933-2-8. PubMed PMID: 15904534; PubMed Central PMCID: PMCPMC1166571.

8.   Shagan BP. Is diabetes a model for aging? Med Clin North Am. 1976;60[6]:1209-11. PubMed PMID: 979401.

9.   Cerami A. Hypothesis. Glucose as a mediator of aging. J Am Geriatr Soc. 1985;33[9]:626-34. PubMed PMID: 3897348.

10.   Mooradian AD. Tissue specificity of premature aging in diabetes mellitus. The role of cellular replicative capacity. J Am Geriatr Soc. 1988;36[9]:831-9. PubMed PMID: 3045190.

11.   Pincus T, Sokka T, Wolfe F. Premature mortality in patients with rheumatoid arthritis: evolving concepts. Arthritis Rheum. 2001;44[6]:1234-6. doi: 10.1002/1529-0131[200106]44:6<1234::AID-ART213>3.0.CO;2-R. PubMed PMID: 11407680.

12.   Navarro-Cano G, Del Rincón I, Pogosian S, Roldán JF, Escalante A. Association of mortality with disease severity in rheumatoid arthritis, independent of comorbidity. Arthritis Rheum. 2003;48[9]:2425-33. doi: 10.1002/art.11127. PubMed PMID: 13130461.

13.   Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol. 2008;26[5 Suppl 51]:S35-61. doi: 2452 [pii]. PubMed PMID: 19026144.

14.   Gonzalez A, Maradit Kremers H, Crowson CS, Nicola PJ, Davis JM, Therneau TM, et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum. 2007;56[11]:3583-7. doi: 10.1002/art.22979. PubMed PMID: 17968923.

15.   McClintock D, Ratner D, Lokuge M, Owens DM, Gordon LB, Collins FS, et al. The mutant form of lamin A that causes Hutchinson-Gilford progeria is a biomarker of cellular aging in human skin. PLoS One. 2007;2[12]:e1269. doi: 10.1371/journal.pone.0001269. PubMed PMID: 18060063; PubMed Central PMCID: PMCPMC2092390.

16.   Korf B. Hutchinson-Gilford progeria syndrome, aging, and the nuclear lamina. N Engl J Med. 2008;358[6]:552-5. doi: 358/6/552 [pii]
10.1056/NEJMp0800071. PubMed PMID: 18256390.

17.   Chung HY, Sung B, Jung KJ, Zou Y, Yu BP. The molecular inflammatory process in aging. Antioxid Redox Signal. 2006;8[3-4]:572-81. doi: 10.1089/ars.2006.8.572. PubMed PMID: 16677101.

18.   Lu T, Pan Y, Kao SY, Li C, Kohane I, Chan J, et al. Gene regulation and DNA damage in the ageing human brain. Nature. 2004;429[6994]:883-91. doi: nature02661 [pii]
10.1038/nature02661. PubMed PMID: 15190254.

19.   Hara MR, Kovacs JJ, Whalen EJ, Rajagopal S, Strachan RT, Grant W, et al. A stress response pathway regulates DNA damage through β[2]-adrenoreceptors and β-arrestin-1. Nature. 2011. doi: nature10368 [pii]
10.1038/nature10368. PubMed PMID: 21857681.

20.   Groeschel M, Braam B. Connecting chronic and recurrent stress to vascular dysfunction: no relaxed role for the renin-angiotensin system. Am J Physiol Renal Physiol. 2011;300[1]:F1-10. doi: ajprenal.00208.2010 [pii]
10.1152/ajprenal.00208.2010. PubMed PMID: 20980410.

21.   Dhabhar FS. Enhancing versus suppressive effects of stress on immune function: implications for immunoprotection and immunopathology. Neuroimmunomodulation. 2009;16[5]:300-17. doi: 000216188 [pii]
10.1159/000216188. PubMed PMID: 19571591; PubMed Central PMCID: PMCPMC2790771.

22.   Dragoş D, Tănăsescu MD. The effect of stress on the defense systems. J Med Life. 2010;3[1]:10-8. PubMed PMID: 20302192; PubMed Central PMCID: PMCPMC3019042.

23.   Curtis BJ, Radek KA. Cholinergic Regulation of Keratinocyte Innate Immunity and Permeability Barrier Integrity: New Perspectives in Epidermal Immunity and Disease. J Invest Dermatol. 2011. doi: jid2011264 [pii]
10.1038/jid.2011.264. PubMed PMID: 21918536.

24.	Flint MS, Budiu RA, Teng PN, Sun M, Stolz DB, Lang M, et al. Restraint stress and stress hormones significantly impact T lymphocyte migration and function through specific alterations of the actin cytoskeleton. Brain Behav Immun. 2011;25[6]:1187-96. doi: S0889-1591[11]00077-8 [pii] 10.1016/j.bbi.2011.03.009. PubMed PMID: 21426930.

25.	Radek KA. Antimicrobial anxiety: the impact of stress on antimicrobial immunity. J Leukoc Biol. 2010;88[2]:263-77. doi: jlb.1109740 [pii] 10.1189/jlb.1109740. PubMed PMID: 20442225; PubMed Central PMCID: PMCPMC2908944.

26.	Grando SA, Pittelkow MR, Schallreuter KU. Adrenergic and cholinergic control in the biology of epidermis: physiological and clinical significance. J Invest Dermatol. 2006;126[9]:1948-65. doi: 5700151 [pii] 10.1038/sj.jid.5700151. PubMed PMID: 16912692.

27.	Hearing VJ. Determination of melanin synthetic pathways. J Invest Dermatol. 2011;131[E1]:E8-E11. doi: skinbio.2011.4 [pii] 10.1038/skinbio.2011.4. PubMed PMID: 22094404.

28.	Millington GW. Proopiomelanocortin [POMC]: the cutaneous roles of its melanocortin products and receptors. Clin Exp Dermatol. 2006;31[3]:407-12. doi: CED2128 [pii] 10.1111/j.1365-2230.2006.02128.x. PubMed PMID: 16681590.

29.	Fisher GJ, Kang S, Varani J, Bata-Csorgo Z, Wan Y, Datta S, et al. Mechanisms of photoaging and chronological skin aging. Arch Dermatol. 2002;138[11]:1462-70. doi: dre20020 [pii]. PubMed PMID: 12437452.

30.	Carrasco GA, Van de Kar LD. Neuroendocrine pharmacology of stress. Eur J Pharmacol. 2003;463[1-3]:235-72. doi: S0014299903012858 [pii]. PubMed PMID: 12600714.

31.	Altemus M, Rao B, Dhabhar FS, Ding W, Granstein RD. Stress-induced changes in skin barrier function in healthy women. J Invest Dermatol. 2001;117[2]:309-17. doi: jid1373 [pii] 10.1046/j.1523-1747.2001.01373.x. PubMed PMID: 11511309.

32.	Aguilera G, Kiss A, Sunar-Akbasak B. Hyperreninemic hypoaldosteronism after chronic stress in the rat. J Clin Invest. 1995;96[3]:1512-9. doi: 10.1172/JCI118189. PubMed PMID: 7657823; PubMed Central PMCID: PMCPMC185776.

33.	Aguilera G, Kiss A, Luo X, Akbasak BS. The renin angiotensin system and the stress response. Ann N Y Acad Sci. 1995;771:173-86. PubMed PMID: 8597396.

34.	Clamage DM, Sanford CS, Vander AJ, Mouw DR. Effects of psychosocial stimuli on plasma renin activity in rats. Am J Physiol. 1976;231[4]:1290-4. PubMed PMID: 988755.

35.	Clamage DM, Vander AJ, Mouw DR. Psychosocial stimuli and human plasma renin activity. Psychosom Med. 1977;39[6]:393-401. PubMed PMID: 594285.

36.	Arck PC, Slominski A, Theoharides TC, Peters EM, Paus R. Neuroimmunology of stress: skin takes center stage. J Invest Dermatol. United States2006. p. 1697-704.

37.	Bilbo SD, Nelson RJ. Sex differences in photoperiodic and stress-induced enhancement of immune function in Siberian hamsters. Brain Behav Immun. 2003;17[6]:462-72. doi: S0889159103000631 [pii]. PubMed PMID: 14583238.

38.	Bierhaus A, Wolf J, Andrassy M, Rohleder N, Humpert PM, Petrov D, et al. A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci U S A. 2003;100[4]:1920-5. doi: 0438019100 [pii] 10.1073/pnas.0438019100. PubMed PMID: 12578963; PubMed Central PMCID: PMCPMC149934.

39.	Li H, Smalligan DA, Xie NC, Javer A, Zhang Y, Hanley G, et al. beta-Arrestin 2-Mediated Immune Suppression Induced by Chronic Stress. Neuroimmunomodulation. 2011;18[3]:142-9. doi: 10.1159/000322868. PubMed PMID: WOS:000288340300002.

40.	Charmandari E, Tsigos C, Chrousos G. Endocrinology of the stress response. Annu Rev Physiol. 2005;67:259-84. doi: 10.1146/annurev.physiol.67.040403.120816. PubMed PMID: 15709959.

41.	Flint MS, Baum A, Chambers WH, Jenkins FJ. Induction of DNA damage, alteration of DNA repair and transcriptional activation by stress hormones. Psychoneuroendocrinology. 2007;32[5]:470-9. doi: S0306-4530[07]00054-6 [pii] 10.1016/j.psyneuen.2007.02.013. PubMed PMID: 17459596.

42.	Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006;12[8]:939-44. doi: nm1447 [pii] 10.1038/nm1447. PubMed PMID: 16862152.

43.	Fratiglioni L, Paillard-Borg S, Winblad B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol. 2004;3[6]:343-53. doi: S1474442204007677 [pii] 10.1016/S1474-4422[04]00767-7. PubMed PMID: 15157849.

44.	Kinney DK, Munir KM, Crowley DJ, Miller AM. Prenatal stress and risk for autism. Neurosci Biobehav Rev. 2008;32[8]:1519-32. doi: S0149-7634[08]00098-5 [pii]

10.1016/j.neubiorev.2008.06.004. PubMed PMID: 18598714; PubMed Central PMCID: PMCPMC2632594.

45.   Li H, Smalligan DA, Xie N, Javer A, Zhang Y, Hanley G, et al. β-Arrestin 2-mediated immune suppression induced by chronic stress. Neuroimmunomodulation. 2011;18[3]:142-9. doi: 000322868 [pii] 10.1159/000322868. PubMed PMID: 21228603; PubMed Central PMCID: PMCPMC3031150.

46.   Anwar A, Norris DA, Fujita M. Ubiquitin proteasomal pathway mediated degradation of p53 in melanoma. Arch Biochem Biophys. 2011. Epub 2010/12/21. doi: S0003-9861[10]00509-6 [pii] 10.1016/j.abb.2010.12.012. PubMed PMID: 21167122.

47.   Ji Z, Njauw CN, Taylor M, Neel V, Flaherty KT, Tsao H. p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition. J Invest Dermatol. 2012;132[2]:356-64. doi: jid2011313 [pii] 10.1038/jid.2011.313. PubMed PMID: 21993556.

48.   Tavana O, Benjamin CL, Puebla-Osorio N, Sang M, Ullrich SE, Ananthaswamy HN, et al. Absence of p53-dependent apoptosis leads to UV radiation hypersensitivity, enhanced immunosuppression and cellular senescence. Cell Cycle. 2010;9[16]:3328-36. doi: 12688 [pii] 10.4161/cc.9.16.12688. PubMed PMID: 20703098; PubMed Central PMCID: PMCPMC3041166.

49.   Recent advances and future perspectives in the management of lung cancer. Current Problems in Surgery. 2005;42[8]:548-610.

50.   Sivamani RK, Pullar CE, Manabat-Hidalgo CG, Rocke DM, Carlsen RC, Greenhalgh DG, et al. Stress-Mediated Increases in Systemic and Local Epinephrine Impair Skin Wound Healing: Potential New Indication for Beta Blockers. Plos Medicine. 2009;6[1]:105-15. doi: e1000012 10.1371/journal.pmed.1000012. PubMed PMID: WOS:000262811100017.

51.   Denda M, Fuziwara S, Inoue K. Beta2-adrenergic receptor antagonist accelerates skin barrier recovery and reduces epidermal hyperplasia induced by barrier disruption. J Invest Dermatol. 2003;121[1]:142-8. doi: 12310 [pii] 10.1046/j.1523-1747.2003.12310.x. PubMed PMID: 12839574.

52.   Dhabhar FS, Saul AN, Daugherty C, Holmes TH, Bouley DM, Oberyszyn TM. Short-term stress enhances cellular immunity and increases early resistance to squamous cell carcinoma. Brain Behav Immun. 2010;24[1]:127-37. doi: S0889-1591[09]00426-7 [pii] 10.1016/j.bbi.2009.09.004. PubMed PMID: 19765644; PubMed Central PMCID: PMCPMC2788066.

53.   Dhabhar FS. A hassle a day may keep the pathogens away: The fight-or-flight stress response and the augmentation of immune function. Integr Comp Biol. 2009;49[3]:215-36. doi: icp045 [pii] 10.1093/icb/icp045. PubMed PMID: 21665815.

54.   Dhabhar FS. Stress, leukocyte trafficking, and the augmentation of skin immune function. Ann N Y Acad Sci. 2003;992:205-17. PubMed PMID: 12794060.

55.   Dhabhar FS. Acute stress enhances while chronic stress suppresses skin immunity. The role of stress hormones and leukocyte trafficking. Ann N Y Acad Sci. 2000;917:876-93. PubMed PMID: 11268419.

56.   Dhabhar FS, Satoskar AR, Bluethmann H, David JR, McEwen BS. Stress-induced enhancement of skin immune function: A role for gamma interferon. Proc Natl Acad Sci U S A. 2000;97[6]:2846-51. doi: 050569397 [pii] 10.1073/pnas.050569397. PubMed PMID: 10706626; PubMed Central PMCID: PMCPMC16018.

57.   Dhabhar FS, McEwen BS. Enhancing versus suppressive effects of stress hormones on skin immune function. Proc Natl Acad Sci U S A. 1999;96[3]:1059-64. PubMed PMID: 9927693; PubMed Central PMCID: PMCPMC15350.

58.   Viswanathan K, Dhabhar FS. Stress-induced enhancement of leukocyte trafficking into sites of surgery or immune activation. Proc Natl Acad Sci U S A. 2005;102[16]:5808-13. doi: 0501650102 [pii] 10.1073/pnas.0501650102. PubMed PMID: 15817686; PubMed Central PMCID: PMCPMC556309.

59.   Dhabhar FS. Stress-induced augmentation of immune function--the role of stress hormones, leukocyte trafficking, and cytokines. Brain Behav Immun. 2002;16[6]:785-98. doi: S0889159102000363 [pii]. PubMed PMID: 12480507.

60.   Dhabhar FS, McEwen BS. Acute stress enhances while chronic stress suppresses cell-mediated immunity in vivo: a potential role for leukocyte trafficking. Brain Behav Immun. 1997;11[4]:286-306. doi: S0889-1591[97]90508-0 [pii] 10.1006/brbi.1997.0508. PubMed PMID: 9512816.

61.   Glaser R, Padgett DA, Litsky ML, Baiocchi RA, Yang EV, Chen M, et al. Stress-associated changes in the steady-state expression of latent Epstein-Barr virus: implications for chronic fatigue syndrome and cancer. Brain Behav Immun. 2005;19[2]:91-103. doi: S0889-1591[04]00126-6 [pii] 10.1016/j.bbi.2004.09.001. PubMed PMID: 15664781.

62.   Glaser R, Kiecolt-Glaser JK. Stress-induced immune dysfunction: implications for health. Nat Rev Immunol. 2005;5[3]:243-51. doi: nri1571 [pii] 10.1038/nri1571. PubMed PMID: 15738954.

63.   Quan N, Avitsur R, Stark JL, He L, Shah M, Caligiuri M, et al. Social stress increases the susceptibility to endotoxic shock. J Neuroimmunol. 2001;115[1-2]:36-45. doi: S0165572801002739 [pii]. PubMed PMID: 11282152.

64.   Reiche EM, Nunes SO, Morimoto HK. Stress, depression, the immune system, and cancer. Lancet Oncol. 2004;5[10]:617-25. doi: S1470204504015979 [pii]
10.1016/S1470-2045[04]01597-9. PubMed PMID: 15465465.

65.   Shi Y, Devadas S, Greeneltch KM, Yin D, Allan Mufson R, Zhou JN. Stressed to death: implication of lymphocyte apoptosis for psychoneuroimmunology. Brain Behav Immun. 2003;17 Suppl 1:S18-26. doi: S0889159102000624 [pii]. PubMed PMID: 12615182.

66.   Yin D, Tuthill D, Mufson RA, Shi Y. Chronic restraint stress promotes lymphocyte apoptosis by modulating CD95 expression. J Exp Med. 2000;191[8]:1423-8. PubMed PMID: 10770807; PubMed Central PMCID: PMCPMC2193134.

67.   Yin D, Zhang Y, Stuart C, Miao J, Li C, Zeng X, et al. Chronic restraint stress modulates expression of genes in murine spleen. J Neuroimmunol. 2006;177[1-2]:11-7. doi: S0165-5728[06]00187-1 [pii]
10.1016/j.jneuroim.2006.05.004. PubMed PMID: 16814870.

68.   Zhang Y, Miao J, Hanley G, Stuart C, Sun X, Chen T, et al. Chronic restraint stress promotes immune suppression through toll-like receptor 4-mediated phosphoinositide 3-kinase signaling. J Neuroimmunol. 2008;204[1-2]:13-9. doi: S0165-5728[08]00386-X [pii]
10.1016/j.jneuroim.2008.08.011. PubMed PMID: 18814920; PubMed Central PMCID: PMCPMC2614832.

69.   Zhang Y, Foster R, Sun X, Yin Q, Li Y, Hanley G, et al. Restraint stress induces lymphocyte reduction through p53 and PI3K/NF-kappaB pathways. J Neuroimmunol. 2008;200[1-2]:71-6. doi: S0165-5728[08]00193-8 [pii]
10.1016/j.jneuroim.2008.06.014. PubMed PMID: 18653242; PubMed Central PMCID: PMCPMC2605653.

70.   Zorrilla EP, Luborsky L, McKay JR, Rosenthal R, Houldin A, Tax A, et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun. 2001;15[3]:199-226. doi: S0889-1591[00]90597-X [pii]
10.1006/brbi.2000.0597. PubMed PMID: 11566046.

71.   Naliboff BD, Benton D, Solomon GF, Morley JE, Fahey JL, Bloom ET, et al. Immunological changes in young and old adults during brief laboratory stress. Psychosom Med. 1991;53[2]:121-32. PubMed PMID: 2031066.

72.   Redwine L, Snow S, Mills P, Irwin M. Acute psychological stress: effects on chemotaxis and cellular adhesion molecule expression. Psychosom Med. 2003;65[4]:598-603. PubMed PMID: 12883110.

73.   Redwine L, Mills PJ, Sada M, Dimsdale J, Patterson T, Grant I. Differential immune cell chemotaxis responses to acute psychological stress in Alzheimer caregivers compared to non-caregiver controls. Psychosom Med. 2004;66[5]:770-5. doi: 66/5/770 [pii]
10.1097/01.psy.0000138118.62018.87. PubMed PMID: 15385705.

74.   Mills PJ, Goebel M, Rehman J, Irwin MR, Maisel AS. Leukocyte adhesion molecule expression and T cell naïve/memory status following isoproterenol infusion. J Neuroimmunol. 2000;102[2]:137-44. doi: S0165572899001800 [pii]. PubMed PMID: 10636482.

75.   Bosch JA, Ring C, de Geus EJ, Veerman EC, Amerongen AV. Stress and secretory immunity. Int Rev Neurobiol. 2002;52:213-53. PubMed PMID: 12498106.

76.   Dimsdale JE, Ziegler M, Mills P. Renin correlates with blood pressure reactivity to stressors. Neuropsychopharmacology. 1990;3[4]:237-42. PubMed PMID: 2205227.

77.   Ardaillou R. Angiotensin II receptors. J Am Soc Nephrol. 1999;10 Suppl 11:S30-9. PubMed PMID: 9892138.

78.   Dimsdale JE. Psychological stress and cardiovascular disease. J Am Coll Cardiol. 2008;51[13]:1237-46. doi: S0735-1097[08]00258-1 [pii]
10.1016/j.jacc.2007.12.024. PubMed PMID: 18371552; PubMed Central PMCID: PMCPMC2633295.

79.   Cheng ZJ, Vapaatalo H, Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit. 2005;11[6]:RA194-205. doi: 5504 [pii]. PubMed PMID: 15917731.

80.   Finocchiaro LM, Goldstein DJ, Finkielman S, Nahmod VE. Interaction of angiotensin II with the cholinergic and noradrenergic systems in the rat pineal gland: regulation of indole metabolism. J Endocrinol. 1990;126[1]:59-66. PubMed PMID: 2380655.

81.   Hahn AW, Jonas U, Bühler FR, Resink TJ. Activation of human peripheral monocytes by angiotensin II. FEBS Lett. 1994;347[2-3]:178-80. doi: 0014-5793[94]00531-1 [pii]. PubMed PMID: 7518396.

82.   Mateo T, Naim Abu Nabah Y, Losada M, Estellés R, Company C, Bedrina B, et al. A critical role for TNFalpha in the selective attachment of mononuclear leukocytes to angiotensin-II-stimulated arterioles. Blood. 2007;110[6]:1895-902. doi: blood-2007-01-070607 [pii]
10.1182/blood-2007-01-070607. PubMed PMID: 17595330.

83. Schmeisser A, Soehnlein O, Illmer T, Lorenz HM, Eskafi S, Roerick O, et al. ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-kappaB activity and AT1 receptor expression. Biochem Biophys Res Commun. 2004;325[2]:532-40. doi: S0006-291X[04]02383-6 [pii] 10.1016/j.bbrc.2004.10.059. PubMed PMID: 15530425.

84. Tone A, Shikata K, Ogawa D, Sasaki S, Nagase R, Sasaki M, et al. Changes of gene expression profiles in macrophages stimulated by angiotensin II--angiotensin II induces MCP-2 through AT1-receptor. J Renin Angiotensin Aldosterone Syst. 2007;8[1]:45-50. doi: 2697 [pii] 10.3317/jraas.2007.007. PubMed PMID: 17487826.

85. He M, He X, Xie Q, Chen F, He S. Angiotensin II induces the expression of tissue factor and its mechanism in human monocytes. Thromb Res. 2006;117[5]:579-90. doi: S0049-3848[05]00205-7 [pii] 10.1016/j.thromres.2005.04.033. PubMed PMID: 15953627.

86. Napoleone E, Di Santo A, Camera M, Tremoli E, Lorenzet R. Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. Circ Res. 2000;86[2]:139-43. PubMed PMID: 10666408.

87. Schena M, Mulatero P, Schiavone D, Mengozzi G, Tesio L, Chiandussi L, et al. Vasoactive hormones induce nitric oxide synthase mRNA expression and nitric oxide production in human endothelial cells and monocytes. Am J Hypertens. 1999;12[4 Pt 1]:388-97. doi: S0895-7061[98]00254-4 [pii]. PubMed PMID: 10232499.

88. Yanagitani Y, Rakugi H, Okamura A, Moriguchi K, Takiuchi S, Ohishi M, et al. Angiotensin II type 1 receptor-mediated peroxide production in human macrophages. Hypertension. 1999;33[1 Pt 2]:335-9. PubMed PMID: 9931126.

89. El Bekay R, Alvarez M, Monteseirín J, Alba G, Chacón P, Vega A, et al. Oxidative stress is a critical mediator of the angiotensin II signal in human neutrophils: involvement of mitogen-activated protein kinase, calcineurin, and the transcription factor NF-kappaB. Blood. 2003;102[2]:662-71. doi: 2002-09-2785 [pii] 10.1182/blood-2002-09-2785. PubMed PMID: 12663441.

90. Jethon A, Pula B, Piotrowska A, Wojnar A, Rys J, Dziegiel P, et al. Angiotensin II Type 1 Receptor [AT-1R] Expression Correlates with VEGF-A and VEGF-D Expression in Invasive Ductal Breast Cancer. Pathol Oncol Res. 2012. doi: 10.1007/s12253-012-9516-x. PubMed PMID: 22581182.

91. Akhavan MM, Karimi M, Ghodrati M, Falahtpishe H. AT1 receptors activation enhances the expression of MMP-2, MMP-13 and VEGF but not MMP-9 in B16F10 melanoma cells. Pak J Biol Sci. 2011;14[17]:821-30. PubMed PMID: 22590832.

92. Rodrigues-Ferreira S, Abdelkarim M, Dillenburg-Pilla P, Luissint AC, di-Tommaso A, Deshayes F, et al. Angiotensin II Facilitates Breast Cancer Cell Migration and Metastasis. PLoS One. 2012;7[4]:e35667. doi: PONE-D-12-02354 [pii] 10.1371/journal.pone.0035667. PubMed PMID: 22536420; PubMed Central PMCID: PMCPMC3334979.

93. Hazan-Halevy I, Levy T, Wolak T, Lubarsky I, Levy R, Paran E. Stimulation of NADPH oxidase by angiotensin II in human neutrophils is mediated by ERK, p38 MAP-kinase and cytosolic phospholipase A2. J Hypertens. 2005;23[6]:1183-90. doi: 00004872-200506000-00013 [pii]. PubMed PMID: 15894894.

94. Hallevi H, Hazan-Halevy I, Paran E. Modification of neutrophil adhesion to human endothelial cell line in acute ischemic stroke by dipyridamole and candesartan. Eur J Neurol. 2007;14[9]:1002-7. doi: ENE1847 [pii] 10.1111/j.1468-1331.2007.01847.x. PubMed PMID: 17718692.

95. Paragh G, Szabó J, Kovács E, Keresztes T, Kárpáti I, Balogh Z, et al. Altered signal pathway in angiotensin II-stimulated neutrophils of patients with hypercholesterolaemia. Cell Signal. 2002;14[9]:787-92. doi: S0898656802000177 [pii]. PubMed PMID: 12034360.

96. Alba G, El Bekay R, Chacón P, Reyes ME, Ramos E, Oliván J, et al. Heme oxygenase-1 expression is down-regulated by angiotensin II and under hypertension in human neutrophils. J Leukoc Biol. 2008;84[2]:397-405. doi: jlb.0108035 [pii] 10.1189/jlb.0108035. PubMed PMID: 18515325.

97. Darvin ME, Fluhr JW, Schanzer S, Richter H, Patzelt A, Meinke MC, et al. Dermal carotenoid level and kinetics after topical and systemic administration of antioxidants: Enrichment strategies in a controlled in vivo study. J Dermatol Sci. 2011;64[1]:53-8. doi: S0923-1811[11]00200-3 [pii] 10.1016/j.jdermsci.2011.06.009. PubMed PMID: 21763110.

98. Palmer DM, Kitchin JS. Oxidative damage, skin aging, antioxidants and a novel antioxidant rating system. J Drugs Dermatol. 2010;9[1]:11-5. PubMed PMID: 20120419.

99. Kawaguchi Y, Tanaka H, Okada T, Konishi H, Takahashi M, Ito M, et al. Effect of reactive oxygen species on the elastin mRNA expression in cultured human dermal fibroblasts. Free Radic Biol Med. 1997;23[1]:162-5. doi: S0891-5849[96]00570-9 [pii]. PubMed PMID: 9165309.

100. Monboisse JC, Poulin G, Braquet P, Randoux A, Ferradini C, Borel JP. Effect of oxy radicals on several types of collagen. Int J Tissue React. 1984;6[5]:385-90. PubMed PMID: 6097560.

101.   Sander CS, Chang H, Hamm F, Elsner P, Thiele JJ. Role of oxidative stress and the antioxidant network in cutaneous carcinogenesis. Int J Dermatol. 2004;43[5]:326-35. doi: IJD2222 [pii]
10.1111/j.1365-4632.2004.02222.x. PubMed PMID: 15117361.
102.   Krinsky NI. Mechanism of action of biological antioxidants. Proc Soc Exp Biol Med. 1992;200[2]:248-54. PubMed PMID: 1579590.
103.   Ndiaye M, Philippe C, Mukhtar H, Ahmad N. The grape antioxidant resveratrol for skin disorders: promise, prospects, and challenges. Arch Biochem Biophys. 2011;508[2]:164-70. doi: S0003-9861[10]00527-8 [pii]
10.1016/j.abb.2010.12.030. PubMed PMID: 21215251; PubMed Central PMCID: PMCPMC3060966.
104.   Schafer FQ, Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med. 2001;30[11]:1191-212. doi: S0891584901004804 [pii]. PubMed PMID: 11368918.
105.   Lee YJ, Shacter E. Oxidative stress inhibits apoptosis in human lymphoma cells. J Biol Chem. 1999;274[28]:19792-8. PubMed PMID: 10391922.
106.   Sies H, Cadenas E. Oxidative stress: damage to intact cells and organs. Philos Trans R Soc Lond B Biol Sci. 1985;311[1152]:617-31. PubMed PMID: 2869521.
107.   Wullaert A, Bonnet MC, Pasparakis M. NF-κB in the regulation of epithelial homeostasis and inflammation. Cell Res. 2011;21[1]:146-58. doi: cr2010175 [pii]
10.1038/cr.2010.175. PubMed PMID: 21151201.
108.   Dandona P, Kumar V, Aljada A, Ghanim H, Syed T, Hofmayer D, et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab. 2003;88[9]:4496-501. PubMed PMID: 12970329.
109.   Christian JB, Lapane KL, Hume AL, Eaton CB, Weinstock MA. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial. Journal of the National Cancer Institute. 2008;100[17]:1223-32.
110.   Choi CH, Park YA, Choi JJ, Song T, Song SY, Lee YY, et al. Angiotensin II type I receptor and miR-155 in endometrial cancers: Synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells. Gynecol Oncol. 2012. doi: S0090-8258[12]00275-2 [pii]
10.1016/j.ygyno.2012.04.020. PubMed PMID: 22525818.
111.   Takahashi S, Uemura H, Seeni A, Tang M, Komiya M, Long N, et al. Therapeutic targeting of angiotensin II receptor type 1 to regulate androgen receptor in prostate cancer. Prostate. 2012. doi: 10.1002/pros.22505. PubMed PMID: 22430461.
112.   Kahan V, Andersen ML, Tomimori J, Tufik S. Can poor sleep affect skin integrity? Med Hypotheses. 2010;75[6]:535-7. doi: S0306-9877[10]00246-X [pii]
10.1016/j.mehy.2010.07.018. PubMed PMID: 20678867.
113.   Boscaro M, Barzon L, Fallo F, Sonino N. Cushing's syndrome. Lancet. 2001;357[9258]:783-91. doi: S0140-6736[00]04172-6 [pii]
10.1016/S0140-6736[00]04172-6. PubMed PMID: 11253984.
114.   Roupe G. [Skin of the aging human being]. Lakartidningen. 2001;98[10]:1091-5. PubMed PMID: 11301975.
115.   Pratsinis H, Dimozi A, Pilichos K, Tsagarakis S, Yiacoumettis AM, Kletsas D. Previous chronic exogenous glucocorticoid administration in vivo does not affect functional characteristics and cellular lifespan of human skin fibroblasts in vitro. Exp Dermatol. 2011;20[6]:529-31. doi: 10.1111/j.1600-0625.2011.01262.x. PubMed PMID: 21410774.
116.   Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med. 1993;119[12]:1198-208. PubMed PMID: 8239251.
117.   Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. Lancet. 2006;367[9522]:1605-17. doi: S0140-6736[06]68699-6 [pii]
10.1016/S0140-6736[06]68699-6. PubMed PMID: 16698415.
118.   Schoepe S, Schäcke H, May E, Asadullah K. Glucocorticoid therapy-induced skin atrophy. Exp Dermatol. 2006;15[6]:406-20. doi: EXD435 [pii]
10.1111/j.0906-6705.2006.00435.x. PubMed PMID: 16689857.
119.   Averbeck M, Gebhardt C, Anderegg U, Simon JC. Suppression of hyaluronan synthase 2 expression reflects the atrophogenic potential of glucocorticoids. Exp Dermatol. 2010;19[8]:757-9. doi: EXD1099 [pii]
10.1111/j.1600-0625.2010.01099.x. PubMed PMID: 20659158.
120.   Oikarinen A, Haapasaari KM, Sutinen M, Tasanen K. The molecular basis of glucocorticoid-induced skin atrophy: topical glucocorticoid apparently decreases both collagen synthesis and the corresponding collagen mRNA level in human skin in vivo. Br J Dermatol. 1998;139[6]:1106-10. PubMed PMID: 9990383.

121.   Aberg KM, Radek KA, Choi EH, Kim DK, Demerjian M, Hupe M, et al. Psychological stress downregulates epidermal antimicrobial peptide expression and increases severity of cutaneous infections in mice. J Clin Invest. 2007;117[11]:3339-49. Epub 2007/11/03. doi: 10.1172/jci31726. PubMed PMID: 17975669; PubMed Central PMCID: PMC2045593.

122.   Choi EH, Brown BE, Crumrine D, Chang S, Man MQ, Elias PM, et al. Mechanisms by which psychologic stress alters cutaneous permeability barrier homeostasis and stratum corneum integrity. J Invest Dermatol. United States2005. p. 587-95.

123.   Gerstein AD, Phillips TJ, Rogers GS, Gilchrest BA. Wound healing and aging. Dermatol Clin. 1993;11[4]:749-57. PubMed PMID: 8222358.

124.   Lavker RM, Zheng PS, Dong G. Morphology of aged skin. Clin Geriatr Med. 1989;5[1]:53-67. PubMed PMID: 2646002.

125.   Lefstin JA, Yamamoto KR. Allosteric effects of DNA on transcriptional regulators. Nature. 1998;392[6679]:885-8. doi: 10.1038/31860. PubMed PMID: 9582068.

126.   Beato M, Chalepakis G, Schauer M, Slater EP. DNA regulatory elements for steroid hormones. J Steroid Biochem. 1989;32[5]:737-47. PubMed PMID: 2661921.

127.   De Bosscher K, Vanden Berghe W, Vermeulen L, Plaisance S, Boone E, Haegeman G. Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc Natl Acad Sci U S A. 2000;97[8]:3919-24. doi: 97/8/3919 [pii]. PubMed PMID: 10760263; PubMed Central PMCID: PMCPMC18117.

128.   Schüle R, Rangarajan P, Kliewer S, Ransone LJ, Bolado J, Yang N, et al. Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell. 1990;62[6]:1217-26. doi: 0092-8674[90]90397-W [pii]. PubMed PMID: 2169353.

129.   Tuckermann JP, Reichardt HM, Arribas R, Richter KH, Schütz G, Angel P. The DNA binding-independent function of the glucocorticoid receptor mediates repression of AP-1-dependent genes in skin. J Cell Biol. 1999;147[7]:1365-70. PubMed PMID: 10613894; PubMed Central PMCID: PMCPMC2174255.

130.   Sheu HM, Lee JY, Chai CY, Kuo KW. Depletion of stratum corneum intercellular lipid lamellae and barrier function abnormalities after long-term topical corticosteroids. Br J Dermatol. 1997;136[6]:884-90. PubMed PMID: 9217821.

131.   Kolbe L, Kligman AM, Schreiner V, Stoudemayer T. Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin. Skin Res Technol. 2001;7[2]:73-7. PubMed PMID: 11393207.

132.   Choi EH, Demerjian M, Crumrine D, Brown BE, Mauro T, Elias PM, et al. Glucocorticoid blockade reverses psychological stress-induced abnormalities in epidermal structure and function. Am J Physiol Regul Integr Comp Physiol. United States2006. p. R1657-62.

133.   Maestroni GJ. Sympathetic nervous system influence on the innate immune response. Ann N Y Acad Sci. 2006;1069:195-207. doi: 1069/1/195 [pii]
10.1196/annals.1351.017. PubMed PMID: 16855146.

134.   Slominski A, Wortsman J. Neuroendocrinology of the skin. Endocr Rev. 2000;21[5]:457-87. PubMed PMID: 11041445.

135.   Kawashima K, Fujii T. Expression of non-neuronal acetylcholine in lymphocytes and its contribution to the regulation of immune function. Front Biosci. 2004;9:2063-85. doi: 1390 [pii]. PubMed PMID: 15353271.

136.   Lai Y, Gallo RL. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol. 2009;30[3]:131-41. doi: S1471-4906[09]00005-2 [pii]
10.1016/j.it.2008.12.003. PubMed PMID: 19217824; PubMed Central PMCID: PMCPMC2765035.

137.   Radek KA, Lopez-Garcia B, Hupe M, Niesman IR, Elias PM, Taupenot L, et al. The neuroendocrine peptide catestatin is a cutaneous antimicrobial and induced in the skin after injury. J Invest Dermatol. 2008;128[6]:1525-34. doi: 5701225 [pii]
10.1038/sj.jid.5701225. PubMed PMID: 18185531; PubMed Central PMCID: PMCPMC2757066.

138.   Radek KA, Elias PM, Taupenot L, Mahata SK, O'Connor DT, Gallo RL. Neuroendocrine nicotinic receptor activation increases susceptibility to bacterial infections by suppressing antimicrobial peptide production. Cell Host Microbe. 2010;7[4]:277-89. doi: S1931-3128[10]00106-X [pii]
10.1016/j.chom.2010.03.009. PubMed PMID: 20413096; PubMed Central PMCID: PMCPMC2916230.

139.   Rattan SI. Increased molecular damage and heterogeneity as the basis of aging. Biol Chem. 2008;389[3]:267-72. doi: 10.1515/BC.2008.030. PubMed PMID: 18208348.

140.   Sejersen H, Rattan SI. Dicarbonyl-induced accelerated aging in vitro in human skin fibroblasts. Biogerontology. 2009;10[2]:203-11. doi: 10.1007/s10522-008-9172-4. PubMed PMID: 18758988.

141.   Berge U, Behrens J, Rattan SI. Sugar-induced premature aging and altered differentiation in human epidermal keratinocytes. Ann N Y Acad Sci. 2007;1100:524-9. doi: 1100/1/524 [pii]

10.1196/annals.1395.058. PubMed PMID: 17460218.

142. Rattan SI, Ali RE. Hormetic prevention of molecular damage during cellular aging of human skin fibroblasts and keratinocytes. Ann N Y Acad Sci. 2007;1100:424-30. doi: 1100/1/424 [pii] 10.1196/annals.1395.047. PubMed PMID: 17460207.

143. Rattan SI, Sejersen H, Fernandes RA, Luo W. Stress-mediated hormetic modulation of aging, wound healing, and angiogenesis in human cells. Ann N Y Acad Sci. 2007;1119:112-21. doi: 1119/1/112 [pii] 10.1196/annals.1404.005. PubMed PMID: 18056960.

144. Sejersen H, Rattan SI. Glyoxal-induced premature senescence in human fibroblasts. Ann N Y Acad Sci. 2007;1100:518-23. doi: 1100/1/518 [pii] 10.1196/annals.1395.057. PubMed PMID: 17460217.

145. Rattan SI. Theories of biological aging: genes, proteins, and free radicals. Free Radic Res. 2006;40[12]:1230-8. doi: U612176808538538 [pii] 10.1080/10715760600911303. PubMed PMID: 17090411.

146. Rattan SI, Clark BF. Understanding and modulating ageing. IUBMB Life. 2005;57[4-5]:297-304. doi: W0602N7426W3G262 [pii] 10.1080/15216540500092195. PubMed PMID: 16036613.

147. Calabrese EJ, Bachmann KA, Bailer AJ, Bolger PM, Borak J, Cai L, et al. Biological stress response terminology: Integrating the concepts of adaptive response and preconditioning stress within a hormetic dose-response framework. Toxicol Appl Pharmacol. 2007;222[1]:122-8. doi: S0041-008X[07]00103-2 [pii] 10.1016/j.taap.2007.02.015. PubMed PMID: 17459441.

148. Mattson MP. Hormesis defined. Ageing Res Rev. 2008;7[1]:1-7. doi: S1568-1637[07]00071-2 [pii] 10.1016/j.arr.2007.08.007. PubMed PMID: 18162444; PubMed Central PMCID: PMCPMC2248601.

149. Babizhayev MA, Deyev AI, Savel'yeva EL, Lankin VZ, Yegorov YE. Skin beautification with oral non-hydrolized versions of carnosine and carcinine: Effective therapeutic management and cosmetic skincare solutions against oxidative glycation and free-radical production as a causal mechanism of diabetic complications and skin aging. J Dermatolog Treat. 2011. doi: 10.3109/09546634.2010.521812. PubMed PMID: 21756141.

150. Wolff SP, Dean RT. Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. Biochem J. 1987;245[1]:243-50. PubMed PMID: 3117042; PubMed Central PMCID: PMCPMC1148106.

151. Harman D. The aging process. Proc Natl Acad Sci U S A. 1981;78[11]:7124-8. PubMed PMID: 6947277; PubMed Central PMCID: PMCPMC349208.

152. Makrantonaki E, Zouboulis CC. Molecular mechanisms of skin aging: state of the art. Ann N Y Acad Sci. 2007;1119:40-50. doi: 1119/1/40 [pii] 10.1196/annals.1404.027. PubMed PMID: 18056953.

153. Gunin AG, Kornilova NK, Vasilieva OV, Petrov VV. Age-related changes in proliferation, the numbers of mast cells, eosinophils, and cd45-positive cells in human dermis. J Gerontol A Biol Sci Med Sci. 2011;66[4]:385-92. doi: glq205 [pii] 10.1093/gerona/glq205. PubMed PMID: 21106704.

154. Giacomoni PU, Rein G. Factors of skin ageing share common mechanisms. Biogerontology. 2001;2[4]:219-29. PubMed PMID: 11868897.

155. Montagna W, Carlisle K. Structural changes in ageing skin. Br J Dermatol. 1990;122 Suppl 35:61-70. PubMed PMID: 2186788.

156. Heijnen CJ, Kavelaars A, Kuis W. [The relationship between the neuroendocrine system and juvenile chronic arthritis: a hypothesis]. Tijdschr Kindergeneeskd. 1991;59[5]:182-5. PubMed PMID: 1720265.

157. Minor RR. Collagen metabolism: a comparison of diseases of collagen and diseases affecting collagen. Am J Pathol. 1980;98[1]:225-80. PubMed PMID: 6985771; PubMed Central PMCID: PMCPMC1903399.

158. Matsushima K, Bano M, Kidwell WR, Oppenheim JJ. Interleukin 1 increases collagen type IV production by murine mammary epithelial cells. J Immunol. 1985;134[2]:904-9. PubMed PMID: 3871221.

159. Postlethwaite AE, Lachman LB, Mainardi CL, Kang AH. Interleukin 1 stimulation of collagenase production by cultured fibroblasts. J Exp Med. 1983;157[2]:801-6. PubMed PMID: 6296266; PubMed Central PMCID: PMCPMC2186943.

160. Postlethwaite AE, Smith GN, Mainardi CL, Seyer JM, Kang AH. Lymphocyte modulation of fibroblast function in vitro: stimulation and inhibition of collagen production by different effector molecules. J Immunol. 1984;132[5]:2470-7. PubMed PMID: 6609200.

161. Schmidt JA, Mizel SB, Cohen D, Green I. Interleukin 1, a potential regulator of fibroblast proliferation. J Immunol. 1982;128[5]:2177-82. PubMed PMID: 6460819.

162.   Giacomoni PU. Ageing, science and the cosmetics industry. The micro-inflammatory model serves as a basis for developing effective anti-ageing products for the skin. EMBO Rep. 2005;6 Spec No:S45-8. doi: 7400400 [pii] 10.1038/sj.embor.7400400. PubMed PMID: 15995662; PubMed Central PMCID: PMCPMC1369266.

163.   Chan YC, Leung PS. Angiotensin II type 1 receptor-dependent nuclear factor-kappaB activation-mediated proinflammatory actions in a rat model of obstructive acute pancreatitis. J Pharmacol Exp Ther. 2007;323[1]:10-8. doi: jpet.107.124891 [pii] 10.1124/jpet.107.124891. PubMed PMID: 17616560.

164.   Dhabhar F, McEwen B, editors. Bi-directional effects of stress on immune function: possible explanations for salubrious as well as harmful effects. 4th ed. San Diego: Academic; 2007.

165.   Martin-Ezquerra G, Man MQ, Hupe M, Rodriguez-Martin M, Youm JK, Trullas C, et al. Psychological stress regulates antimicrobial peptide expression by both glucocorticoid and beta-adrenergic mechanisms. Eur J Dermatol. France2011. p. 48-51.

166.   Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacological Reviews. 2008;60[1]:79-127.

167.   Farris PK. Innovative cosmeceuticals: sirtuin activators and anti-glycation compounds. Semin Cutan Med Surg. 2011;30[3]:163-6. doi: S1085-5629[11]00073-3 [pii] 10.1016/j.sder.2011.05.004. PubMed PMID: 21925370.

168.   Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5[6]:493-506. doi: nrd2060 [pii] 10.1038/nrd2060. PubMed PMID: 16732220.

169.   Caltagirone S, Rossi C, Poggi A, Ranelletti FO, Natali PG, Brunetti M, et al. Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer. 2000;87[4]:595-600. Epub 2000/08/05. doi: 10.1002/1097-0215[20000815]87:4<595::AID-IJC21>3.0.CO;2-5 [pii]. PubMed PMID: 10918203.

170.   Estrov Z, Shishodia S, Faderl S, Harris D, Van Q, Kantarjian HM, et al. Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood. 2003;102[3]:987-95. doi: 2002-11-3550 [pii] 10.1182/blood-2002-11-3550. PubMed PMID: 12689943.

171.   Kaya G, Saurat JH. Dermatoporosis: A new concept in skin aging. European Geriatric Medicine. 2010;1[4]:216-9. doi: 10.1016/j.eurger.2010.06.002. PubMed PMID: WOS:000287673200004.

172.   Barone E, Calabrese V, Mancuso C. Ferulic acid and its therapeutic potential as a hormetin for age-related diseases. Biogerontology. 2009;10[2]:97-108. doi: 10.1007/s10522-008-9160-8. PubMed PMID: 18651237.

173.   Cecchi T, Cecchi P, Passamonti P. The first quantitative rating system of the antioxidant capacity of beauty creams via the Briggs-Rauscher reaction: a crucial step towards evidence-based cosmetics. Analyst. 2011;136[3]:613-8. doi: 10.1039/c0an00637h. PubMed PMID: 21125090.

174.   Chiu A, Kimball AB. Topical vitamins, minerals and botanical ingredients as modulators of environmental and chronological skin damage. British Journal of Dermatology. 2003;149[4]:681-91.

175.   Matsui MS, Hsia A, Miller JD, Hanneman K, Scull H, Cooper KD, et al. Non-sunscreen photoprotection: antioxidants add value to a sunscreen. J Investig Dermatol Symp Proc. 2009;14[1]:56-9. doi: jidsymp200914 [pii] 10.1038/jidsymp.2009.14. PubMed PMID: 19675555.

176.   Rattmann YD, Mendéz-Sánchez SC, Furian AF, Paludo KS, de Souza LM, Dartora N, et al. Standardized extract of Dicksonia sellowiana Presl. Hook [Dicksoniaceae] decreases oxidative damage in cultured endothelial cells and in rats. J Ethnopharmacol. 2011;133[3]:999-1007. doi: S0378-8741[10]00815-9 [pii] 10.1016/j.jep.2010.11.030. PubMed PMID: 21094243.

177.   Jackson RL, Greiwe JS, Schwen RJ. Ageing skin: oestrogen receptor β agonists offer an approach to change the outcome. Exp Dermatol. 2011;20[11]:879-82. doi: 10.1111/j.1600-0625.2011.01362.x. PubMed PMID: 21913999.

178.   Bingham MM, Saltzman B, Vo NJ, Perkins JA. Propranolol Reduces Infantile Hemangioma Volume and Vessel Density. Otolaryngol Head Neck Surg. 2012. doi: 0194599812451570 [pii] 10.1177/0194599812451570. PubMed PMID: 22691693.

179.   Chisholm KM, Chang KW, Truong MT, Kwok S, West RB, Heerema-McKenney AE. β-Adrenergic receptor expression in vascular tumors. Mod Pathol. 2012. doi: modpathol2012108 [pii] 10.1038/modpathol.2012.108. PubMed PMID: 22743651.

180.   Chim H, Armijo BS, Miller E, Gliniak C, Serret MA, Gosain AK. Propranolol Induces Regression of Hemangioma Cells Through HIF-1α-Mediated Inhibition of VEGF-A. Ann Surg. 2012. doi: 10.1097/SLA.0b013e318254ce7a. PubMed PMID: 22580939.

181.   Wolosker N, de Campos JR, Kauffman P, Neves S, Munia MA, BiscegliJatene F, et al. The use of oxybutynin for treating axillary hyperhidrosis. Ann Vasc Surg. 2011;25[8]:1057-62. doi: S0890-5096[11]00391-8 [pii] 10.1016/j.avsg.2011.06.007. PubMed PMID: 22023940.

182.   Wolosker N, de Campos JR, Kauffman P, Puech-Leão P. A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis. J Vasc Surg. 2012;55[6]:1696-700. doi: S0741-5214[11]03085-0 [pii] 10.1016/j.jvs.2011.12.039. PubMed PMID: 22341836.

183.   Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol. 2010;146[10]:1141-50. doi: 146/10/1141 [pii] 10.1001/archdermatol.2010.256. PubMed PMID: 20956649.

184.   Rossi A, Cantisani C, Melis L, Iorio A, Scali E, Calvieri S. Minoxidil use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov. 2012;6[2]:130-6. doi: IAD-EPUB-20120308-001 [pii]. PubMed PMID: 22409453.

185.   Webers CA, Beckers HJ, Zeegers MP, Nuijts RM, Hendrikse F, Schouten JS. The intraocular pressure-lowering effect of prostaglandin analogs combined with topical β-blocker therapy: a systematic review and meta-analysis. Ophthalmology. 2010;117[11]:2067-74.e1-6. doi: S0161-6420[10]00271-X [pii] 10.1016/j.ophtha.2010.03.024. PubMed PMID: 20619459.

186.   Cohen JL. Enhancing the growth of natural eyelashes: the mechanism of bimatoprost-induced eyelash growth. Dermatol Surg. 2010;36[9]:1361-71. doi: DSU1522 [pii] 10.1111/j.1524-4725.2010.01522.x. PubMed PMID: 20384750.

187.   Gopaul R, Knaggs HE, Lephart JF, Holley KC, Gibson EM. An evaluation of the effect of a topical product containing salicin on the visible signs of human skin aging. J Cosmet Dermatol. 2010;9[3]:196-201. doi: 10.1111/j.1473-2165.2010.00512.x. PubMed PMID: 20883292.

188.   Azfar RS, Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol. 2008;20[4]:416-22. doi: 00002281-200807000-00008 [pii] 10.1097/BOR.0b013e3283031c99. PubMed PMID: 18525354.

189.   Gelfand JM, Dommasch ED, Shin DB, Azfar RS, Kurd SK, Wang X, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol. 2009;129[10]:2411-8. doi: jid2009112 [pii] 10.1038/jid.2009.112. PubMed PMID: 19458634; PubMed Central PMCID: PMCPMC2864921.

190.   Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000;35[3]:569-82. doi: S0735109799006300 [pii]. PubMed PMID: 10716457.

191.   Druppel V, Kusche-Vihrog K, Grossmann C, Gekle M, Kasprzak B, Brand E. Long-term application of the aldosterone antagonist spironolactone prevents stiff endothelial cell syndrome. The FASEB Journal. Published online May 31 article fj.13-228312 [Epub ahead of print]. PubMed PMID: 23729588